Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA) (T-140/12)
Judgment
Law
The plea alleging infringement of Arti…
52

Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA) (T-140/12)

Judgment of 22 Jan 2015law://eu/cjeu/2012/t-140-12/para_52@2026-11-11

52In the present case, the applicants contend that the COMP’s summary report of 8 November 2007 and its opinion of 14 November 2007 are unlawful, which contention they repeated at the hearing.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: General Court · Sixth Chamber
Case: T-140/12 · ECLI:EU:T:2015:41
Decided: 22 Jan 2015
Procedure: Action for annulment
Applicants: Teva Pharma BV; Teva Pharmaceuticals Europe BV
Defendant: European Medicines Agency (EMA)
Rapporteur: S. Frimodt Nielsen
Bench: 3 judges
S. Frimodt Nielsen, F. Dehousse, A.M. Collins
Language: English
Official: CURIA · EUR-Lex 62012TJ0140

Topics

Pharmaceutical and cosmetic products Public health

History · 1 version

22 Jan 2015Reading

Connections

Cited by 12: Sanofi BV, anciennement Genzyme Europe BV v European Commission (T-483/22); Landesbank Baden-Württemberg v Single Resolution Board (T-142/22); UniCredit Bank GmbH, formerly UniCredit Bank AG v Single Resolution Board (T-402/21); Volkskreditbank AG v Single Resolution Board (T-348/21); Hypo Vorarlberg Bank AG v Single Resolution Board (T-347/21); Nadya Rauff-Nisthar v European Commission (T-341/21); Mylan IRE Healthcare Ltd v European Commission (T-303/16); Pharmaceutical Works Polpharma S.A. v European Medicines Agency (T-611/18)2 provisions; GMP-Orphan (GMPO) v European Commission (T-733/17); Bristol-Myers Squibb Pharma EEIG v European Commission and European Medicines Agency (T-329/16); Shire Pharmaceuticals Ireland Ltd v European Medicines Agency (T-80/16); Teva Pharma BV and Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA) (C-138/15)
Cites 18: Treaty on the Functioning of the European Union (consolidated 2016)2 provisions; Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; Walzstahl-Vereinigung and Thyssen Aktiengesellschaft v Commission of the European Communities (140/82, 146/82, 221/82, 226/82); Tresplain Investments Ltd v Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) (T-303/08); SpA Simmenthal v Commission of the European Communities (92/78); Italian Republic v Council of the European Economic Community and Commission of the European Economic Community (32/65); Sina Bank v Council of the European Union (T-15/11); Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products; Commission Regulation (EC) No 847/2000 of 27 April 2000 laying down the provisions for implementation of the criteria for designation of a medicinal product as an orphan medicinal product and definitions of the concepts 'similar medicinal product' and 'clinical superiority'; Now Pharm AG v European Commission (T-74/08); Gütermann AG and Zwicky & Co. AG v European Commission (T-456/05); Andreas Reinarz v European Commission (T-6/92, T-52/92); Kirsten Andersen and Others v European Parliament (262/80); Télévision française 1 (TF1) and Others v European Commission (T-520/09); Macchiorlati Dalmas & Figli v High Authority of the European Coal and Steel Community (21/64); CSL Behring GmbH v European Commission and European Medicines Agency (EMA) (T-264/07); Alsace International Car Service (AICS) v European Parliament (T-139/99); Anton Dürbeck GmbH v Commission of the European Communities (T-252/97)